A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral TP-271 in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 24 Jul 2019
Price : $35 *
At a glance
- Drugs TP 271 (Primary)
- Indications Bacterial infections; Community-acquired pneumonia
- Focus Adverse reactions
- Sponsors Tetraphase Pharmaceuticals
- 18 Jul 2019 Status changed from recruiting to completed.
- 16 Apr 2019 Results presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
- 03 May 2018 According to the Tetraphase Pharmaceuticals media release, company expect to complete this trial in 2H 2018.